Aislinn Antrim, Assistant Managing Editor from Pharmacy Times - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats		NCPA 2024: Enabling Clinical Program Growth Requires a Change in Mindset - 22 days ago FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome - 2 months ago Food As Medicine Can Change Patient Lives, But Establishing Models, Payment Pathways Is Critical - 3 months ago Real-World Evidence Shows 82% Reduction in Infant RSV Hospitalizations With Nirsevimab - 7 months ago Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure - 7 months ago Study: Empagliflozin Reduces MACE Regardless of Baseline Albuminuria Levels - 7 months ago Pharmacy Technicians, Advanced Techs Can Do More in the Pharmacy - 8 months ago Changing Mindset Is Crucial for Clinicians to Effectively Implement New Weight Management Medications - 8 months ago AI, Machine Learning Can Bring Significant Benefits to Pharmaceutical Development, Research - 8 months ago “Food Is Medicine” Movement Takes Off - 8 months ago FDA Grants Accelerated Approval to Zanubrutinib for Relapsed, Refractory Follicular Lymphoma - 9 months ago Pharmacists Play Vital Role in Improving Vaccine Equity - 9 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 10 months ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - 10 months ago The Future of Immunotherapy in Breast Cancer Involves Engineered T-Cell Therapies, Better Prediction of Adverse Effects - 12 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - 12 months ago Adding Pembrolizumab to Chemotherapy Increased Pathological Complete Response, Improved Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2- Breast Cancer - 12 months ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - 12 months ago Study: Patients With PD-L1-Positive, High-Risk, ER+/HER2- Breast Cancer Can Achieve Substantial Complete Response Rates With Addition of Nivolumab - 12 months ago MONALEESA Pooled Analyses Show Quality of Life Is Maintained in Elderly Patients Receiving Ribociclib, Endocrine Therapy - 12 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 12 months ago Experts Say More Research Is Needed to Understand Obesity-Cancer Link - 12 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - 12 months ago FDA Issues Fast Track Designation to ADP101 for Mono-, Multi-Food Allergies - 12 months ago FDA Approves Tirzepatide for Chronic Weight Management - about 1 year ago FDA Approves Secukinumab for Hidradenitis Suppurativa - about 1 year ago Study Links Long COVID With Short Sleep Duration - about 1 year ago FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive Adults - about 1 year ago Scholarship Program Aims to Improve Diversity, Equity in Pharmacy Field - about 1 year ago FDA Approves Secukinumab as First Intravenous Interleukin-17A Antagonist for Rheumatic Diseases - about 1 year ago Study Finds IVIG, Therapeutic Plasma Exchange Have Comparable Efficacy for Neurological Disorders - about 1 year ago Survey Highlights Need for Improved Working Conditions, Communication in Pharmacies - about 1 year ago Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma - about 1 year ago Phase 3 Trial Reinforces Favorability of Roflumilast Cream 0.05% for Atopic Dermatitis in Children - about 1 year ago Study: Shared Decision-Making in Cardiovascular Health is Infrequently Utilized, Despite Benefits - about 1 year ago